Evidence map›Paper›PMID 32323316›Full record

ArticleActa obstetricia et gynecologica Scandinavica2020

Do fetal extravillous trophoblasts circulate in maternal blood postpartum?

Anne van de Looij, Ripudaman Singh, Lotte Hatt, Katarina Ravn, Line D Jeppesen, Bolette H Nicolaisen, Mathias Kølvraa, Ida Vogel, Palle Schelde, Niels Uldbjerg

Open access · hybridAbstract read
In one paragraph

Article in Acta obstetricia et gynecologica Scandinavica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Genetics in prenatal diagnosis.Singapore medical journal · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Do fetal extravillous trophoblasts circulate in maternal blood postpartum?Acta obstetricia et gynecologica Scandinavica · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Anne van de LooijDepartment of Women's Disease and Birth, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-9086-1506
Ripudaman SinghARCEDI Biotech ApS, Vejle, Denmark.ORCID 0000-0003-2657-0661
Lotte HattARCEDI Biotech ApS, Vejle, Denmark.ORCID 0000-0003-0141-9172
Katarina RavnARCEDI Biotech ApS, Vejle, Denmark.ORCID 0000-0001-5428-8781
Line D JeppesenARCEDI Biotech ApS, Vejle, Denmark.
Bolette H NicolaisenARCEDI Biotech ApS, Vejle, Denmark.
Mathias KølvraaARCEDI Biotech ApS, Vejle, Denmark.ORCID 0000-0002-7177-7234
Ida VogelDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-1125-0393
Palle ScheldeARCEDI Biotech ApS, Vejle, Denmark.ORCID 0000-0001-8504-0893
Niels UldbjergDepartment of Women's Disease and Birth, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-6449-6426
Aarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCirculating fetal extravillous trophoblasts may offer a superior alternative to cell-free fetal DNA for noninvasive prenatal testing. Cells of fetal origin are a pure source of fetal genome; hence, unlike the cell-free noninvasive prenatal test, the fetal cell-based noninvasive prenatal test is not expected to be affected by maternal DNA. However, circulating fetal cells from previous pregnancies may lead to confounding results. MATERIAL AND

methodsTo study whether fetal trophoblast cells persist in maternal circulation postpartum, blood samples were collected from 11 women who had given birth to a boy, with blood sampling at 1-3 days (W0), 4-5 weeks (W4-5), around 8 weeks (W8) and around 12 weeks (W12) postpartum. The existence of fetal extravillous trophoblasts was verified either by X and Y chromosome fluorescence in situ hybridization analysis or by short tandem repeat analysis. To exclude technological bias in isolating fetal cells, blood samples were also collected from 10 pregnant women between a gestational age of 10 and 14 weeks, the optimal time frame for cell-based noninvasive prenatal test sampling. All the samples were processed according to protocols established by ARCEDI Biotech for fetal extravillous trophoblast enrichment and isolation.

resultsFetal extravillous trophoblasts were found in all the 10 samples from pregnant women between a gestational age of 10 and 14 weeks. However, only 4 of 11 blood samples taken from women at 1-3 days postpartum rendered fetal extravillous trophoblasts, and only 2 of 11 samples rendered fetal extravillous trophoblasts at 4 weeks postpartum.

conclusionsIn this preliminary dataset on few pregnancies, none of the samples rendered any fetal cells at or after 8 weeks postpartum, showing that cell-based noninvasive prenatal testing based on fetal extravillous trophoblasts is unlikely to be influenced by circulating cells from previous pregnancies.

Indexed as

Cell CountFemaleFetusHumansIn Situ Hybridization, FluorescenceMaleMicrosatellite RepeatsPolymerase Chain ReactionPostpartum PeriodPregnancyTrophoblastschorionic villi samplingfetal cellsfetal extravillous trophoblastsnoninvasive prenatal testingprenatal diagnosis

Identifiers

PMID32323316
PMCPMC7384123
OpenAlexW3017515556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.